title: Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
abstract: Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate cancer (CRPC), responses are variable and short-lived. There is an urgent need to understand the basis of resistance to optimize their future use. We reasoned that a radiopharmaceutical that measures intratumoral changes in AR signaling could substantially improve our understanding of AR pathway directed therapies. Expanding on previous observations, we first show that prostate-specific membrane antigen (PSMA) is repressed by androgen treatment in multiple models of AR-positive prostate cancer in an AR-dependent manner. Conversely, antiandrogens up-regulate PSMA expression. These expression changes, including increased PSMA expression in response to treatment with the antiandrogen MDV3100, can be quantitatively measured in vivo in human prostate cancer xenograft models through PET imaging with a fully humanized, radiolabeled antibody to PSMA, (64)Cu-J591. Collectively, these results establish that relative changes in PSMA expression levels can be quantitatively measured using a human-ready imaging reagent and could serve as a biomarker of AR signaling to noninvasively evaluate AR activity in patients with CRPC.
authors: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors: Michael J
authors: MJ
authors: Evans
authors: Peter M
authors: PM
authors: Smith-Jones
authors: John
authors: J
authors: Wongvipat
authors: Vincent
authors: V
authors: Navarro
authors: Sae
authors: S
authors: Kim
authors: Neil H
authors: NH
authors: Bander
authors: Steven M
authors: SM
authors: Larson
authors: Charles L
authors: CL
authors: Sawyers
references: Urology. 1996 Aug;48(2):326-34
references: 8753752
references: Gene. 2002 Feb 20;285(1-2):247-56
references: 12039052
references: Cancer Res. 2007 May 15;67(10):5033-41
references: 17510436
references: Expert Opin Investig Drugs. 2001 Mar;10(3):511-9
references: 11227049
references: Clin Cancer Res. 2010 Dec 15;16(24):6093-9
references: 20975102
references: Clin Cancer Res. 2007 May 1;13(9):2707-13
references: 17473203
references: J Clin Oncol. 2005 Jul 20;23(21):4591-601
references: 15837970
references: Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7233-8
references: 19363158
references: J Nucl Med. 2004 Jan;45(1):17-21
references: 14734662
references: J Clin Oncol. 2010 Mar 20;28(9):1489-95
references: 20159823
references: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references: 16278481
references: J Nucl Med. 2004 Mar;45(3):366-73
references: 15001675
references: Nat Rev Cancer. 2008 Apr;8(4):268-78
references: 18337732
references: Curr Opin Pharmacol. 2008 Aug;8(4):440-8
references: 18674639
references: Science. 2009 May 8;324(5928):787-90
references: 19359544
references: Lancet. 2010 Apr 24;375(9724):1437-46
references: 20398925
references: J Nucl Med. 2010 Aug;51(8):1293-300
references: 20660376
references: Cancer Res. 2000 Sep 15;60(18):5237-43
references: 11016653
references: Clin Cancer Res. 2005 Oct 15;11(20):7454-61
references: 16243819
references: J Nucl Med. 2002 Jan;43(1):46-55
references: 11801702
references: J Nucl Med. 2003 Apr;44(4):610-7
references: 12679407
references: Nat Med. 2009 May;15(5):559-65
references: 19363497
references: J Nucl Med. 2004 Mar;45(3):357-65
references: 15001674
references: Cancer Cell. 2010 May 18;17(5):443-54
references: 20478527
references: J Clin Oncol. 2008 May 1;26(13):2147-54
references: 18362364